Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults

Grants

Funding Acknowledgements

This review was funded by Novartis Vaccines and Diagnostics. James Wassil and Veronique Abitbol are employees of Novartis Vaccines and Diagnostics. Peter Dull was an employee of Novartis Vaccines and Diagnostics at the time the manuscript was written and is currently at the Bill and Melinda Gates Foundation. Terry Nolan and Miguel O'Ryan did not receive any monetary incentives from the sponsor with respect to this manuscript. Both their institutions have received research contracts from Novartis to carry out clinical studies of MenB vaccine. The authors have no financial relationships relevant to this review article to disclose.